- Home
- TLPH vs RDHL Comparison
TLPH vs RDHL Comparison
Compare TLPH & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLPH | RDHL |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | Israel |
| Employees | 12 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.6M | 5.4M |
| IPO Year | 2010 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TLPH | RDHL |
|---|---|---|
| Price | $0.78 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 140.9K | 59.4K |
| Earning Date | 05-13-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,151,000.00 | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.71 |
| 52 Week High | $1.57 | $3.31 |
Technical Indicators
Market Signals| Indicator | TLPH | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 48.40 |
| Support Level | $0.73 | $0.92 |
| Resistance Level | $0.87 | $1.07 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.21 | 29.84 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.